12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IV Captisol-enabled Melphalan: Phase II/III started

Ligand began an open-label, U.S. Phase II/III trial to evaluate 100 mg/m 2 IV Captisol-enabled Melphalan for 2 days in 60 patients. The product has Orphan Drug designation as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation. Ligand said it...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >